Sutetinib maleate is the maleate salt form of Sutetinib. This compound functions as an orally effective tyrosine kinase (tyrosine kinase) inhibitor that targets tyrosine kinases associated with tumor growth and angiogenesis, including VEGFR (VEGFR-1/2/3 with Ki=0.009 µM), PDGFR (PDGFR-α/β with Ki=0.008 µM), and the proto-oncogene cKIT. Sutetinib maleate inhibits the proliferation, migration, and tubular structure formation of endothelial and fibroblast cells, displaying antitumor activity across various tumor cell lines.